Cover Image
市場調查報告書

Pluristem Therapeutics Inc.:產品平台分析

Pluristem Therapeutics Inc. - Product Pipeline Review - 2015

出版商 Global Markets Direct 商品編碼 226224
出版日期 內容資訊 英文 33 Pages
訂單完成後即時交付
價格
Back to Top
Pluristem Therapeutics Inc.:產品平台分析 Pluristem Therapeutics Inc. - Product Pipeline Review - 2015
出版日期: 2015年11月18日 內容資訊: 英文 33 Pages
簡介

Pluristem Therapeutics Inc.是利用3D生物反應器來開發人類疾病用細胞療法的生物科技企業。該公司的產品用於治療週邊動脈阻塞性疾病,肌肉疾病等的缺血症。

本報告提供Pluristem Therapeutics Inc.的治療藥開發平台現狀及各開發階段比較分析,提供您藥物標的,作用機制,給藥途徑,各分子類型的治療藥評估,最新的企業新聞和發表,後期階段及中止的計劃等相關資訊。

Pluristem Therapeutics Inc.的基本資料

Pluristem Therapeutics Inc.概要

  • 主要資訊
  • 企業資料

Pluristem Therapeutics Inc.:R&D概要

  • 主要的治療範圍

Pluristem Therapeutics Inc.:開發平台評估

  • 各開發階段的開發中產品
  • 單劑產品

Pluristem Therapeutics Inc.:開發中產品概況

  • 臨床實驗階段的開發中產品
    • 第二階段的產品/聯合治療模式
    • 第一階段的產品/聯合治療模式
  • 初期階段的開發中產品
    • 前臨床階段的產品/聯合治療模式

Pluristem Therapeutics Inc.:藥物簡介

  • PLX-PAD
  • PLXR-18
  • 發炎性腸道疾病幹細胞療法

Pluristem Therapeutics Inc.:開發平台分析

  • 各給藥途徑
  • 各分子類型

Pluristem Therapeutics Inc.:最近的開發平台趨勢

Pluristem Therapeutics Inc.:暫停中的計劃

Pluristem Therapeutics Inc.:總公司和子公司的所在地

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC07702CDB

Summary

Global Markets Direct's, 'Pluristem Therapeutics Inc. - Product Pipeline Review - 2015', provides an overview of the Pluristem Therapeutics Inc.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Pluristem Therapeutics Inc.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of Pluristem Therapeutics Inc. including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of Pluristem Therapeutics Inc.'s human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the Pluristem Therapeutics Inc.'s pipeline products

Reasons to buy

  • Evaluate Pluristem Therapeutics Inc.'s strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of Pluristem Therapeutics Inc. in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the Pluristem Therapeutics Inc.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of Pluristem Therapeutics Inc. and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of Pluristem Therapeutics Inc.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of Pluristem Therapeutics Inc. and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Pluristem Therapeutics Inc. Snapshot
    • Pluristem Therapeutics Inc. Overview
    • Key Information
    • Key Facts
  • Pluristem Therapeutics Inc. - Research and Development Overview
    • Key Therapeutic Areas
  • Pluristem Therapeutics Inc. - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
  • Pluristem Therapeutics Inc. - Pipeline Products Glance
    • Pluristem Therapeutics Inc. - Clinical Stage Pipeline Products
      • Phase II Products/Combination Treatment Modalities
      • Phase I Products/Combination Treatment Modalities
    • Pluristem Therapeutics Inc. - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
  • Pluristem Therapeutics Inc. - Drug Profiles
    • PLX-PAD
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • PLXR-18
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Stem Cell Therapy for Inflammatory Bowel Disease
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Pluristem Therapeutics Inc. - Pipeline Analysis
    • Pluristem Therapeutics Inc. - Pipeline Products by Route of Administration
    • Pluristem Therapeutics Inc. - Pipeline Products by Molecule Type
  • Pluristem Therapeutics Inc. - Recent Pipeline Updates
  • Pluristem Therapeutics Inc. - Dormant Projects
  • Pluristem Therapeutics Inc. - Locations And Subsidiaries
    • Head Office
    • Other Locations & Subsidiaries
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Pluristem Therapeutics Inc., Key Information
  • Pluristem Therapeutics Inc., Key Facts
  • Pluristem Therapeutics Inc. - Pipeline by Indication, 2015
  • Pluristem Therapeutics Inc. - Pipeline by Stage of Development, 2015
  • Pluristem Therapeutics Inc. - Monotherapy Products in Pipeline, 2015
  • Pluristem Therapeutics Inc. - Phase II, 2015
  • Pluristem Therapeutics Inc. - Phase I, 2015
  • Pluristem Therapeutics Inc. - Preclinical, 2015
  • Pluristem Therapeutics Inc. - Pipeline by Route of Administration, 2015
  • Pluristem Therapeutics Inc. - Pipeline by Molecule Type, 2015
  • Pluristem Therapeutics Inc. - Recent Pipeline Updates, 2015
  • Pluristem Therapeutics Inc. - Dormant Developmental Projects,2015
  • Pluristem Therapeutics Inc., Subsidiaries

List of Figures

  • Pluristem Therapeutics Inc. - Pipeline by Top 10 Indication, 2015
  • Pluristem Therapeutics Inc. - Pipeline by Stage of Development, 2015
  • Pluristem Therapeutics Inc. - Monotherapy Products in Pipeline, 2015
  • Pluristem Therapeutics Inc. - Pipeline by Top 10 Route of Administration, 2015
  • Pluristem Therapeutics Inc. - Pipeline by Top 10 Molecule Type, 2015
Back to Top